Valion Bio, Inc. VBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-2.17
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | $780,000 | $1.2M | $1.8M | $1.3M |
| Gross profit | — | $2,000 | $287,000 | $299,000 | -$38,000 |
| Operating income | -$7.9M | -$4.5M | -$8.2M | -$10.1M | -$5.6M |
| Net income | -$8.9M | -$5.7M | -$8.2M | -$10.1M | -$8.5M |
| Operating cash flow | -$7.0M | -$5.7M | -$8.5M | -$8.9M | -$5.6M |
| Free cash flow | -$7.0M | -$5.7M | -$8.6M | -$8.9M | — |
| Total assets | $31.6M | $2.8M | $5.2M | $5.9M | $15.0M |
| Total liabilities | $7.4M | $272,000 | $1.6M | $2.2M | $1.8M |
| Shareholders' equity | $16.8M | $2.5M | $3.6M | $3.6M | $13.3M |
| Ratios | |||||
| Gross margin | — | 0.3% | 24.4% | 16.2% | -3.0% |
| Operating margin | — | -573.8% | -701.1% | -548.8% | -448.1% |
| Net margin | — | -725.0% | -701.0% | -548.7% | -675.7% |
| FCF margin | — | -734.0% | -733.8% | -485.3% | — |
| Return on assets | -28.1% | -201.5% | -159.9% | -171.8% | -56.5% |
| Return on equity | -52.9% | -223.1% | -230.3% | -278.1% | -64.0% |
| Current ratio | 20.13 | 9.70 | 3.32 | 2.83 | 11.72 |
| Revenue growth | — | -33.7% | -36.1% | 46.4% | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.17 (distress)
- Working capital / assets 0.391
- Retained earnings / assets -1.664
- EBIT / assets -0.25
- Equity / liabilities 2.258
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001787740 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.